CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Mifepristone

米非司酮 杂质对照品Mifepristone Impurities

10 个杂质条目10 impurity entries

本页汇总 米非司酮 的 10 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 10 impurity reference standards of Mifepristone. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 米非司酮(Mifepristone)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesStability Indicating RP-HPLC Method by QbD Approach and LC-MS Characterization of Degradation Products of Mifepristone
    Journal of chromatographic science · 2025 · Chandarana C et al.  ·  PMID 40167513  ·  DOI
  2. 杂质研究Impurity studies[Separation and identification of impurities in mifepristone]
    Yao xue xue bao = Acta pharmaceutica Sinica · 1992 · Wu XJ, Song YW  ·  PMID 1293931
  3. 杂质研究Impurity studiesFormulation-Based Repurposing of Mifepristone Using a Drug-Eluting Intrauterine Insert for Localized Uterine Fibroid Therapy: A Preclinical Study
    AAPS PharmSciTech · 2026 · Patel R et al.  ·  PMID 42014532  ·  DOI
  4. 分析方法Analytical MethodsA validated HPLC-MS/MS method for the quantification of systemic mifepristone after subcutaneous application in mice
    Analytical methods : advancing methods and applications · 2024 · Tevini J et al.  ·  PMID 39045617  ·  DOI
  5. 分析方法Analytical MethodsBioequivalence Study of Two Formulations of Mifepristone Tablets in Healthy Chinese Subjects Under Fasting Conditions
    Clinical pharmacology in drug development · 2023 · Li M et al.  ·  PMID 37145969  ·  DOI

米非司酮 —— 原料药与杂质对照品Mifepristone — drug substance & impurities

共 11 个条目(含原料药本体)11 items incl. the drug substance
Mifepristone structure
原料药 APIAPI
米非司酮Mifepristone
Mifepristone
CAS No.84371-65-3
Chemical FormulaC29H35NO2
Purity>95%询价On request
10mg25mg50mg100mg
Mifepristone Impurity 1 structure
1
米非司酮杂质1Mifepristone Impurity 1
Mifepristone Impurity 1
CAS No.1231185-09-3
Chemical FormulaC29H35NO2
Purity>95%询价On request
10mg25mg50mg100mg
Mifepristone Impurity 3 structure
3
米非司酮杂质3Mifepristone Impurity 3
Mifepristone Impurity 3
CAS No.10109-53-2
Chemical FormulaC21H26O2
Purity>95%询价On request
10mg25mg50mg100mg
Mifepristone Impurity 10 structure
10
米非司酮杂质10Mifepristone Impurity 10
Mifepristone Impurity 10
CAS No.104004-96-8
Chemical FormulaC28H33NO2
Purity>95%询价On request
10mg25mg50mg100mg
Mifepristone Impurity 11 structure
11
米非司酮杂质11Mifepristone Impurity 11
Mifepristone Impurity 11
CAS No.104004-92-4
Chemical FormulaC27H31NO2
Purity>95%询价On request
10mg25mg50mg100mg
Mifepristone Impurity 12 structure
12
米非司酮杂质12Mifepristone Impurity 12
Mifepristone Impurity 12
CAS No.84371-64-2
Chemical FormulaC31H41NO4
Purity>95%询价On request
10mg25mg50mg100mg
Mifepristone Impurity 14 structure
14
米非司酮杂质14Mifepristone Impurity 14
Mifepristone Impurity 14
CAS No.105012-15-5
Chemical FormulaC29H35NO3
Purity>95%询价On request
10mg25mg50mg100mg
Mifepristone Impurity 15 structure
15
米非司酮杂质15Mifepristone Impurity 15
Mifepristone Impurity 15
CAS No.104004-98-0
Chemical FormulaC30H39NO4
Purity>95%询价On request
10mg25mg50mg100mg
Mifepristone Impurity 16 structure
16
米非司酮杂质16Mifepristone Impurity 16
Mifepristone Impurity 16
CAS No.91934-95-1
Chemical FormulaC30H39NO4
Purity>95%询价On request
10mg25mg50mg100mg
Mifepristone Impurity 18 structure
18
米非司酮杂质18Mifepristone Impurity 18
Mifepristone Impurity 18
CAS No.91934-98-4
Chemical FormulaC29H35NO3
Purity>95%询价On request
10mg25mg50mg100mg
Mifepristone Impurity 20 structure
20
米非司酮杂质20Mifepristone Impurity 20
Mifepristone Impurity 20
CAS No.123956-01-4
Chemical FormulaC26H31NO2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

米非司酮 —— 研究文献与合成路线Mifepristone — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 米非司酮 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Mifepristone. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Stability Indicating RP-HPLC Method by QbD Approach and LC-MS Characterization of Degradation Products of Mifepristone
    Chandarana C, Juwarwala I, Prajapati P, et al. · Journal of chromatographic science · 2025
  2. Mifepristone inhibits hepatoma growth by enhancing the GR-HSP60-survivin interaction to facilitate survivin degradation
    Huang YH, Lin KH, Lai MW, et al. · Journal of Cancer · 2023 · 被引 3cited 3
  3. [Separation and identification of impurities in mifepristone]
    Wu XJ, Song YW · Yao xue xue bao = Acta pharmaceutica Sinica · 1992

合成与制备工艺专利Synthesis & process patents

  1. Mifepristone medicinal preparation and preparation method thereof
    YANQING YANG, JUNYONG LIU, FANG CHEN, WEIJUN QIAO, et al. · 公开号 CN101455671CN101455671 · 2009
  2. Novel polymorph form M of mifepristone and process for its preparation
    JOSHI NARENDRA S, KHILE ANIL S, PRADHAN NITIN S.C · 公开号 US2007105828US2007105828 · 2007

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

米非司酮 杂质谱研究要点Mifepristone — impurity profiling notes

下面这些是拿到 米非司酮 的 11 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 11 impurity entries for Mifepristone, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances